Down-regulation of insulin-like growth factor binding protein-5 (IGFBP-5): Novel marker for cervical carcinogenesis

International Journal of Cancer

Volumn 120, Issue 10, 2007, Pages 2068-2077

  Miyatake, Takashi ^a   Ueda, Yutaka ^a   Nakashima, Ryuichi ^a   Yoshino, Kiyoshi ^a   Kimura, Toshihiro ^a   Murata, Takuya ^a   Nomura, Taisei ^a   Fujita, Masami ^a   Buzard, Gregory S ^b   Enomoto, Takayuki ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SAIC FREDERICK INC   (United States)

Author keywords

cDNA microarray; Cervical intraepithelial neoplasia (CIN); Human papillomavirus (HPV); Immunohistochemistry; Insulin like growth factor binding protein 5 (IGFBP 5); Real time RT PCR; Squamous cell carcinoma (SCC)

Indexed keywords

COMPLEMENTARY DNA; MESSENGER RNA; PROTEIN P72; SOMATOMEDIN BINDING PROTEIN 5;

ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; GENE; GPC4 GENE; HUMAN; HUMAN TISSUE; IGFBP 5 GENE; IMMUNOHISTOCHEMISTRY; NAB2 GENE; NUCLEOTIDE SEQUENCE; P72 GENE; PRECANCER; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; S100A2 GENE; SQUAMOUS CELL CARCINOMA; TRIM2 GENE; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU;

CARCINOMA, SQUAMOUS CELL; DNA, VIRAL; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 5; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PAPILLOMAVIRUS INFECTIONS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 34147175955     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22264     Document Type: Article

References (75)

1. Jones SB. Cancer in the developing world: a call to action. BMJ 1999;319:505-8.
2. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol 2005;32 (Suppl 1):S16-S24.
3. Pecorelli S, Favalli G, Zigliani L, Odicino F. Cancer in women. Int J Gynecol Obstet 2003;82:369-79.
4. Chan PG, Sung HY, Sawaya GF. Changes in cervical cancer incidence after three decades of screening US women less than 30 years old. Obstet Gynecol 2003;102:765-73.
5. Smith HO, Tiffany MF, Quails CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States - a 24-year population-based study. Gynecol Oncol 2000;78:97-105.
6. Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster W, Kurman RJ. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol 1992; 79:328-37.
7. Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, Gabriel R, Quereux C, Birembaut P. Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women. Br J Cancer 1999;80:1306-11.
8. Motoyama S, Ladines-Llave CA, Luis Villanueva S, Maruo T. The role of human papilloma virus in the molecular biology of cervical carcinogenesis. Kobe J Med Sci 2004;50:9-19.
9. Bedell MA, Jones KH, Laimins LA. The E6-E7 region of human papillomavirus type 18 is sufficient for transformation of NIH 3T3 and rat-1 cells. J Virol 1987;61:3635-40.
10. Phelps WC, Yee CL, Munger K, Howley PM. The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A. Cell 1988;53: 539-47.
11. Spitkovsky D, Aengeneyndt F, Braspenning J, von Knebel Doeberitz K. P53-independent growth regulation of cervical cancer cells by the papillomavirus E6 oncogene. Oncogene 1996;13:1027-35.
12. Storey A, Pim D, Murray A, Osborn K, Banks L, Crawford L. Comparison of the in vitro transforming activities of human papillomavirus types. EMBO J 1988;7:1815-20.
13. Ward P, Coleman DV, Malcolm AD. Regulatory mechanisms of the papillomaviruses. Trends Genet 1989;5:97-9.
14. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000; 92:690-8.
15. Southern SA, Herrington CS. Disruption of cell cycle control by human papillomaviruses with special reference to cervical carcinoma. Int J Gynecol Cancer 2000;10:263-74.
16. Chee M, Yang R, Hubbell E, Berno A, Huang XC, Stern D, Winkler J, Lockhart DJ, Morris MS, Fodor SP. Accessing genetic information with high-density DNA arrays. Science 1996;274:610-14.
17. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995;270:467-70.
18. Napoli C, Lerman LO, Sica V, Lerman A, Tajana G, de Nigris F. Microarray analysis: a novel research tool for cardiovascular scientists and physicians. Heart 2003;89:597-604.
19. Ueda Y, Enomoto T, Miyatake T, Ozaki K, Yoshizaki T, Kanao J, Ueno Y, Nakashima R, Shroyer KR, Murata Y. Monoclonal expansion with integration of high-risk type human papillomaviruses is an initial step for cervical carcinogenesis: association of clonal status and human papillomavirus infection with clinical outcome in cervical intraepithelial neoplasia. Lab Invest 2003;83:1517-27.
20. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, et al. Gene ontology: tool for the unification of biology. The gene ontology consortium. Nat Genet 2000;25:25-9.
21. Lee SW, Tomasetto C, Swisshelm K, Keyomarsi K, Sager R. Down-regulation of a member of the S100 gene family in mammary carcinoma cells and reexpression by azadeoxycytidine treatment. Proc Natl Acad Sci USA 1992;89:2504-8.
22. Schafer BW, Heizmann CW. The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends Biochem Sci 1996; 21:134-40.
23. Lamm GM, Nicol SM, Fuller-Pace FV, Lamond AI. P72: a human nuclear DEAD box protein highly related to p68. Nucleic Acids Res 1996;24:3739-47.
24. Wilson BJ, Bates GJ, Nicol SM, Gregory DJ, Perkins ND, Fuller-Pace FV. The p68 and p72 DEAD box RNA helicases interact with HDAC1 and repress transcription in a promoter-specific manner. BMC Mol Biol 2004;5:11.
25. Kiefer MC, Ioh RS, Bauer DM, Zapf J. Molecular cloning of a new human insulin-like growth factor binding protein. Biochem Biophys Res Commun 1991;176:219-25.
26. Butt AJ, Dickson KA, McDougall F, Baxter RC. Insulin-like growth factor-binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo. J Biol Chem 2003;278:29676-85.
27. Nagase T, Ishikawa K, Miyajima N, Tanaka A, Kotani H, Nomura N, Ohara O. Prediction of the coding sequences of unidentified human genes. IX. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro. DNA Res 1998;5:31-9.
28. Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, Luzi L, Riganelli D, Zanaria E, Messali S, Cainarca S, Guffanti A, Minucci S et al. The tripartite motif family identifies cell compartments. EMBO J 2001; 20:2140-51.
29. Svaren J, Sevetson BR, Apel ED, Zimonjic DB, Popescu NC, Milbrandt J. NAB2, a corepressor of NGFI-A (Egr-1) and Krox20, is induced by proliferative and differentiative stimuli. Mol Cell Biol 1996;16:3545-53.
30. Veugelers M, Vermeesch J, Watanabe K, Yamaguchi Y, Marynen P, David G. GPC4, the gene for human K-glypican, flanks GPC3 on xq26: deletion of the GPC3-GPC4 gene cluster in one family with Simpson-Golabi-Behmel syndrome. Genomics 1998;58:1-11.
31. Huber R, Mazzarella R, Chen CN, Chen E, Ireland M, Lindsay S, Pilia G, Crisponi L. Glypican 3 and glypican 4 are juxtaposed in Xq26.1. Gene 1998;225:9-16.
32. Skubitz KM, Skubitz AP. Differential gene expression in uterine leiomyoma. J Lab Clin Med 2003;141:297-308.
33. Hibbs K, Skubitz KM, Pambuccian SE, Casey RC, Burleson KM, Oegema TR, Jr, Thiele JJ, Grindle SM, Bliss RL, Skubitz AP. Differential gene expression in ovarian carcinoma: identification of potential biomarkers. Am J Pathol 2004;165:397-414.
34. Finley DJ, Zhu B, Fahey TJ, III. Molecular analysis of Hurthle cell neoplasms by gene profiling. Surgery 2004;136:1160-8.
35. Kawamoto S, Ohnishi T, Kita H, Chisaka O, Okubo K. Expression profiling by iAFLP: a PCR-based method for genome-wide gene expression profiling. Genome Res 1999;9:1305-12.
36. Sese J, Nikaidou H, Kawamoto S, Minesaki Y, Morishita S, Okubo K. Body Map incorporated PCR-based expression profiling data and a gene ranking system. Nucleic Acids Res 2001;29:156-8.
37. Saito S, Matoba R, Kato K. Adapter-tagged competitive PCR (ATAC-PCR) - a high-throughput quantitative PCR method for microarray validation. Methods 2003;13:326-31.
38. Kita-Matsuo H, Yukinawa N, Matoba R, Saito S, Oba S, Ishii S, Kato K. Adaptor-tagged competitive polymerase chain reaction: amplification bias and quantified gene expression levels. Anal Biochem 2005; 339:15-28.
39. Santin AD, Zhan F, Bignotti E, Siegel ER, Cane S, Bellone S, Palmieri M, Anfossi S, Thomas M, Burnett M, Kay HH, Roman JJ et al. Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. Virology 2005;331:269-91.
40. Hudelist G, Czerwenka K, Singer C, Pischinger K, Kubista E, Manavi M. cDNA array analysis of cytobrush-collected normal and malignant cervical epithelial cells: a feasibility study. Cancer Genet Cytogenet 2005;158:35-42.
41. Wang H, Hubbell E, Hu JS, Mei G, Cline M, Lu G, Clark T, Siani-Rose MA, Ares M, Kulp DC, Haussler D. Gene structure-based splice variant deconvolution using a microarray platform. Bioinformatics 2003;19 (Suppl 1):i315-i322.
42. Sutcliffe JG, Milner RJ. Alternative mRNA splicing: the Shaker gene. Trends Genet 1988;4:297-9.
43. Croft L, Schandorff S, Clark F, Burrage K, Arctander P, Mattick JS. ISIS, the intron information system, reveals the high frequency of alternative splicing in the human genome. Nat Genet 2000;24:340-1.
44. Hu GK, Madore SJ, Moldover B, Jatkoe T, Balaban D, Thomas J, Wang Y. Predicting splice variant from DNA chip expression data. Genome Res 2001;11:1237-45.
45. Duan C, Xu Q. Roles of insulin-like growth factor (IGF) binding proteins in regulating IGF actions. Gen Comp Endocrinol 2005;142:44-52.
46. Lelbach A, Muzes G, Feher J. The insulin-like growth factor system: IGFs, IGF-binding proteins and IGFBP-proteases. Acta Physiol Hung 2005;92:97-107.
47. Burger AM, Leyland-Jones B, Banerjee K, Spyropoulos DD, Seth AK. Essential roles of IGFBP-3 and IGFBP-rPl in breast cancer. Eur J Cancer 2005;41:1515-27.
48. Allander SV, Larsson C, Ehrenborg E, Suwanichkul A, Weber G, Morris SL, Bajalica S, Kiefer MC, Luthman H, Powell DR. Characterization of the chromosomal gene and promoter for human insulin-like growth factor binding protein-5. Biol Chem 1994;269:10891-8.
49. Drescher B, Zumkeller W, Lauke H, Hartmann M, Davidoff MS. Insulin-like growth factor-binding protein (IGFBP)-5 in human testicular tubules. Adv Exp Med Biol 1997;424:153-4.
50. Wirtz MK, Xu H, Rust K, Alexander JP, Acott TS. Insulin-like growth factor binding protein-5 expression by human trabecular meshwork. Invest Ophthalmol Vis Sci 1998;39:45-53.
51. Allen JT, Bloor CA, Kedia RK, Knight RA, Spiteri MA. Expression of growth hormone-releasing factor, growth hormone, insulin-like growth factor-1 and its binding proteins in human lung. Neuropeptides 2000;34:98-107.
52. Zhou J, Bondy C. Anatomy of the human ovarian insulin-like growth factor system. Biol Reprod 1993;48:467-82.
53. Zhou J, Dsupin BA, Giudice LC, Bondy CA. Insulin-like growth factor, system gene expression in human endometrium during the menstrual cycle. J Clin Endocrinol Metab 1994;79:1723-34.
54. Lee WH, Wang GM, Lo T, Triarhou LC, Ghetti B. Altered IGFBP5 gene expression in the cerebellar external germinal layer of weaver mutant mice. Brain Res Mol Brain Res 1995;30:259-68.
55. Tonner E, Barber MC, Travers MT, Logan A, Flint DJ. Hormonal control of insulin-like growth factor-binding protein-5 production in the involuting mammary gland of the rat. Endocrinology 1997;138: 5101-7.
56. Miyakoshi N, Richman C, Kasukawa Y, Linkhart TA, Baylink DJ, Mohan S. Evidence that IGF-binding protein-5 functions as a growth factor. Clin Invest 2001;107:73-81.
57. Huynh H. Suppression of uterine insulin-like growth factor binding protein 5 by estrogen is mediated in part by insulin-like growth factor I. Int J Oncol 1998;12:427-32.
58. Schneider MR, Wolf E, Hoeflich A, Lahm H. IGF-binding protein-5: flexible player in the IGF system and effector on its own. J Endocrinol 2002;172:423-40.
59. Schedlich LJ, Young TF, Firth SM, Baxter RC. Insulin-like growth factor-binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells. J Biol Chem 1998;273:18347-52.
60. Schedlich LJ, Le Page SL, Firth SM, Briggs LJ, Jans DA, Baxter RC. Nuclear import of insulin-like growth factor-binding protein-3 and -5 is mediated by the importin beta subunit. J Biol Chem 2000;275: 23462-70.
61. Lin SC, Wang CP, Chen YM, Lu SY, Fann MJ, Liu CJ, Kao SY, Chang KW. Regulation of IGFBP-5 expression during tumourigenesis and differentiation of oral keratinocytes. J Pathol 2002;198:317-25.
62. Takahashi M, Papavero V, Yuhas J, Kort E, Kanayama HO, Kagawa S, Baxter RC, Yang XJ, Gray SG, Teh BT. The altered expression of members of the IGF-axis in clear cell renal cell carcinoma. Int J Oncol 2005;26:923-31.
63. Cesi V, Vitali R, Tanno B, Giuffrida ML, Sesti F, Mancini C, Raschella G. Insulin-like growth factor binding protein 5: contribution to growth and differentiation of neuroblastoma cells. Ann N Y Acad Sci 2004;1028:59-68.
64. Mathur SP, Mathur RS, Young RC. Cervical epidermal growth factor-receptor (EGF-R) and serum insulin-like growth factor II (IGF-II) levels are potential markers for cervical cancer. Am J Reprod Immunol 2000;44:222-30.
65. Mathur SP, Mathur RS, Rust PF, Young RC. Human papilloma virus (HPV)-E6/E7 and epidermal growth factor receptor (EGF-R) protein levels in cervical cancer and cervical intraepithelial neoplasia (CIN). Am J Reprod Immunol 2001;46:280-7.
66. Mathur SP, Landen CP, Datta SM, Hoffman MC, Mathur RS, Young RC. Insulin-like growth factor II in gynecological cancers: a preliminary study. Am J Reprod Immunol 2003;49:113-19.
67. Mathur SP, Mathur RS, Gray EA, Lane D, Underwood PG, Kohler M, Creasman WT. Serum vascular endothelial growth factor C (VEGF-C) as a specific biomarker for advanced cervical cancer: relationship to insulin-like growth factor II (IGF-II), IGF binding protein 3 (IGF-BP3) and VEGF-B. Gynecol Oncol 2005;98:467-83.
68. Mathur SP, Mathur RS, Underwood PB, Kohler MF, Creasman WT. Circulating levels of insulin-like growth factor-II and IGF-binding protein 3 in cervical cancer. Gynecol Oncol 2003;91:486-93.
69. Mannhardt B, Weinzimer SA, Wagner M, Fiedler M, Cohen P, Jansen-Durr P, Zwerschke W. Human papillomavirus type 16 E7 oncoprotein binds and inactivates growth-inhibitory insulin-like growth factor binding protein 3. Mol Cell Biol 2000;20:6483-95.
70. Steller MA, Delgado CH, Zou Z. Insulin-like growth factor II mediates epidermal growth factor-induced mitogenesis in cervical cancer cells. Proc Natl Acad Sci USA 1995;92:11970-4.
71. Berger AJ, Baege A, Guillemette T, Deeds J, Meyer R, Disbrow G, Schlegel R. Insulin-like growth factor-binding protein 3 expression increases during immortalization of cervical keratinocytes by human papillomavirus type 16 E6 and E7 proteins. Am J Pathol 2002;161: 603-10.
72. Hirano S, Ito N, Takahashi S, Tamaya T. Clinical implications of insulin-like growth factors through the presence of their binding proteins and receptors expressed in gynecological cancers. Eur J Gynaecol Oncol 2004;25:187-91.
73. Higo H, Duan C, Clemmons DR, Herman B. Retinoic acid inhibits cell growth in HPV negative cervical carcinoma cells by induction of insulin-like growth factor binding protein-5 (IGFBP-5) secretion. Biochem Biophys Res Commun 1997;239:706-9.
74. Nakamura K, Hongo A, Kodama J, Miyagi Y, Yoshinouti M, Kudo T. Down-regulation of the insulin-like growth factor I receptor by antisense RNA can reverse the transformed phenotype of human cervical cancer cell lines. Cancer Res 2000;60:760-5.
75. Shen MR, Lin AC, Hsu YM, Chang TJ, Tang MJ, Alper SL, Ellory JC, Chou CY. Insulin-like growth factor I stimulate KCL cotransport, which is necessary for invasion and proliferation of cervical cancer and ovarian cancer cells. J Biol Chem 2004;279:40017-25.